share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Apr 26 03:21
Summary by Futu AI
Cybin Inc., a clinical-stage biopharmaceutical company, has announced its participation in the 27th Annual Milken Institute Global Conference. The company's CEO, Doug Drysdale, is set to speak on a panel titled "Collaborating for Improved Mental Health" on May 8, 2024. The conference, which addresses global challenges including mental health, will be held from May 5-8, 2024, at the Beverly Hilton in Los Angeles. Cybin is known for its development of psychedelic-based treatments for mental health conditions and has recently received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for major depressive disorder, and is developing CYB004 for generalized anxiety disorder. The company aims to transform mental health treatment and will share its vision and recent advancements at the conference. The panel discussion will be available on Cybin's investor relations website. Cybin, founded in 2019 and headquartered in Canada, operates in multiple countries and focuses on proprietary drug discovery, drug delivery systems, and treatment regimens for mental health disorders.
Cybin Inc., a clinical-stage biopharmaceutical company, has announced its participation in the 27th Annual Milken Institute Global Conference. The company's CEO, Doug Drysdale, is set to speak on a panel titled "Collaborating for Improved Mental Health" on May 8, 2024. The conference, which addresses global challenges including mental health, will be held from May 5-8, 2024, at the Beverly Hilton in Los Angeles. Cybin is known for its development of psychedelic-based treatments for mental health conditions and has recently received FDA Breakthrough Therapy Designation for CYB003, a psilocybin analog for major depressive disorder, and is developing CYB004 for generalized anxiety disorder. The company aims to transform mental health treatment and will share its vision and recent advancements at the conference. The panel discussion will be available on Cybin's investor relations website. Cybin, founded in 2019 and headquartered in Canada, operates in multiple countries and focuses on proprietary drug discovery, drug delivery systems, and treatment regimens for mental health disorders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.